首页> 外文期刊>Journal of research in medical sciences : >ALLELE FREQUENCY AND GENOTYPE DISTRIBUTION OF A COMMON VARIANT IN THE 3'?UNTRANSLATED REGION OF THE SLC22A3 GENE IN PATIENTS WITH TYPE 2 DIABETES: ASSOCIATION WITH RESPONSE TO METFORMIN
【24h】

ALLELE FREQUENCY AND GENOTYPE DISTRIBUTION OF A COMMON VARIANT IN THE 3'?UNTRANSLATED REGION OF THE SLC22A3 GENE IN PATIENTS WITH TYPE 2 DIABETES: ASSOCIATION WITH RESPONSE TO METFORMIN

机译:2型糖尿病患者SLC22A3基因3'非翻译区的等位基因频率和常见变异的基因型分布:对二甲双胍的反应

获取原文
           

摘要

Background: Organic cation transporter 3 (OCT3) is an excellent transporter for metformin, which is used as first-line therapy for type 2 diabetes (T2D). OCT3 genetic variants may influence the clinical response to metformin. This study aimed to determine the genotype and allele frequency of OCT3-564G>A (rs3088442) variant and its role in the glycemic response to metformin in patients with newly diagnosed T2D. Materials and Methods: Based on the response to metformin, 150 patients were classified into two groups: Sixty-nine responders (decrease in glycated hemoglobin [HbA1c] values by more than 1% from the baseline) and 81 nonresponders (decrease in HbA1c values A was genotyped using polymerase chain reaction - based restriction fragment length polymorphism.Results: The genotypes frequencies were 51.3% GG, 36% AG, and 12.7% AA. Allele frequency of major allele (G) and minor allele (A) in OCT3-564G>A variant was found to be 0.69 and 0.31, respectively. Fasting glucose, HbA1c, body mass index, and lipid profile in both GG genotypes and GA+AA group decreased significantly after 3 months of metformin therapy compared with baseline (P 0.05).Conclusion: The A allele frequency (which may be a protective allele against coronary heart disease) in the Iranian diabetic patients was lower than Iranian, Caucasian and Japanese healthy populations. Metformin is useful in improving the lipid profile, in addition to its impacts in glycemic control, and these effects are regardless of OCT3-564G>A variant.
机译:背景:有机阳离子转运蛋白3(OCT3)是二甲双胍的极佳转运蛋白,被用作2型糖尿病(T2D)的一线治疗。 OCT3基因变异可能影响对二甲双胍的临床反应。本研究旨在确定OCT3-564G> A(rs3088442)变异体的基因型和等位基因频率及其在新诊断为T2D的患者中对二甲双胍的血糖反应中的作用。材料和方法:根据对二甲双胍的反应,将150例患者分为两类:69位反应者(糖化血红蛋白[HbA1c]值比基线下降超过1%)和81位​​无反应者(HbA1c值下降A结果:基因型频率为51.3%GG,36%AG和12.7%AA; OCT3-564G中主要等位基因(G)和次要等位基因(A)的等位基因频率>二甲双胍治疗3个月后,GG基因型和GA + AA组的空腹血糖,HbA1c,体重指数和血脂谱分别较基线下降了0.69和0.31(P 0.05)。结论:伊朗糖尿病患者的A等位基因频率(可能是预防冠心病的保护性等位基因)低于伊朗,白种人和日本健康人群,此外,二甲双胍有助于改善血脂水平除了其对血糖控制的影响外,这些影响与OCT3-564G> A变体无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号